Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario

Detalhes bibliográficos
Autor(a) principal: Renni, Marcos Jose Pereira
Data de Publicação: 2019
Outros Autores: Marinho, Tatiana Abelin Saldanha, Souza, Mirian Carvalho de
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/387
Resumo: Cancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients.
id INCA-1_0e1005626ca4dd20391720c950fed416
oai_identifier_str oai:rbc.inca.gov.br:article/387
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this ScenarioTratamiento de Tromboembolismo Venoso en Pacientes con Cáncer: Actualización sobre el Papel de los Anticoagulantes Orales Directos en este EscenarioTratamento do Tromboembolismo Venoso em Pacientes com Câncer: Atualização quanto ao Papel dos Anticoagulantes Orais Diretos nesse CenárioTromboembolia Venosa/tratamento farmacológicoAnticoagulantesNeoplasiasVenous Thromboembolism/drug therapyAnticoagulantsNeoplasmsTromboembolia Venosa/tratamiento farmacológicoAnticoagulantesNeoplasiasCancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients.El cáncer es ampliamente conocido por aumentar el riesgo de complicaciones tromboembólicas. El riesgo estará relacionado con los factores propios del paciente, sus comorbilidades, factores relacionados con el tumor, el momento del tratamiento y sus condiciones clínicas. La terapia anticoagulante debe prescribirse teniendo en cuenta el riesgo de sangrado y recurrencia de TEV. Con la aparición de nuevos anticoagulantes orales y su uso en pacientes con cáncer asociado a trombosis, se han realizado estudios para validar su uso. Sin embargo, deben considerarse los riesgos para proporcionar la terapia más adecuada y segura. Estas alternativas terapéuticas deben publicarse en los servicios de oncología, facilitando así su uso y mayor beneficio para los pacientes.  O câncer é amplamente conhecido por aumentar o risco de complicações tromboembólicas. Esse risco está relacionado às características do próprio paciente, suas comorbidades e condições clínicas, além de fatores relacionados ao tumor e ao momento do tratamento. A terapia anticoagulante deverá ser prescrita levando-se em consideração o risco hemorrágico e de recorrência de trombose venosa profunda (TVP). Estudos  clínicos foram realizados para validar a utilização dos novos anticoagulantes orais diretos (DOAC) em pacientes com câncer associado à trombose (CAT). Entretanto, os riscos devem ser considerados com intuito de fornecer a terapia mais adequada e segura para cada paciente. Essas alternativas terapêuticas deverão ser divulgadas nos serviços de oncologia, facilitando assim sua utilização e maior benefício para os pacientes.INCA2019-10-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo de opniãoapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/38710.32635/2176-9745.RBC.2019v65n3.387Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-04387Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-04387Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-043872176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/387/478https://rbc.inca.gov.br/index.php/revista/article/view/387/605Copyright (c) 2019 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessRenni, Marcos Jose PereiraMarinho, Tatiana Abelin SaldanhaSouza, Mirian Carvalho de2021-11-29T20:03:43Zoai:rbc.inca.gov.br:article/387Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:03:43Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
Tratamiento de Tromboembolismo Venoso en Pacientes con Cáncer: Actualización sobre el Papel de los Anticoagulantes Orales Directos en este Escenario
Tratamento do Tromboembolismo Venoso em Pacientes com Câncer: Atualização quanto ao Papel dos Anticoagulantes Orais Diretos nesse Cenário
title Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
spellingShingle Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
Renni, Marcos Jose Pereira
Tromboembolia Venosa/tratamento farmacológico
Anticoagulantes
Neoplasias
Venous Thromboembolism/drug therapy
Anticoagulants
Neoplasms
Tromboembolia Venosa/tratamiento farmacológico
Anticoagulantes
Neoplasias
title_short Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
title_full Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
title_fullStr Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
title_full_unstemmed Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
title_sort Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
author Renni, Marcos Jose Pereira
author_facet Renni, Marcos Jose Pereira
Marinho, Tatiana Abelin Saldanha
Souza, Mirian Carvalho de
author_role author
author2 Marinho, Tatiana Abelin Saldanha
Souza, Mirian Carvalho de
author2_role author
author
dc.contributor.author.fl_str_mv Renni, Marcos Jose Pereira
Marinho, Tatiana Abelin Saldanha
Souza, Mirian Carvalho de
dc.subject.por.fl_str_mv Tromboembolia Venosa/tratamento farmacológico
Anticoagulantes
Neoplasias
Venous Thromboembolism/drug therapy
Anticoagulants
Neoplasms
Tromboembolia Venosa/tratamiento farmacológico
Anticoagulantes
Neoplasias
topic Tromboembolia Venosa/tratamento farmacológico
Anticoagulantes
Neoplasias
Venous Thromboembolism/drug therapy
Anticoagulants
Neoplasms
Tromboembolia Venosa/tratamiento farmacológico
Anticoagulantes
Neoplasias
description Cancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-24
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigo de opnião
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/387
10.32635/2176-9745.RBC.2019v65n3.387
url https://rbc.inca.gov.br/index.php/revista/article/view/387
identifier_str_mv 10.32635/2176-9745.RBC.2019v65n3.387
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/387/478
https://rbc.inca.gov.br/index.php/revista/article/view/387/605
dc.rights.driver.fl_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-04387
Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-04387
Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-04387
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042243658317824

Registros relacionados